The sequences coding for the pl8 protein of CBL-1, a British human immunodeficiency virus (HIV) type 1 isolate, were expressed in Escherichia coli as fl-galactosidase fusion proteins. The recombinant proteins were used to screen a panel of five monoclonal antibodies (MAbs) raised against pl 8 expressed in CBL-l-infected cells. The regions containing the epitopes for four of the MAbs were located using carboxy deletion mutants and synthetic peptides. The epitope of one of the MAbs (1D9) was reconstructed as part of an unfused, E. coil-expressed p 18 protein using the polymerase chain reaction technique. Four different HIV strains and one lymphadenopathy virus type 2 strain were analysed by fluorescence-activated cell sorting of live infected cells using the plS-reactive MAbs.
INTRODUCTION
Human immunodeficiency virus (HIV) is the primary aetiological agent of AIDS and other diseases (Barre-Sinoussi et al., 1983; Levy et al., 1984; Popovic et al., 1984) . In common with other retroviruses the main components of the HIV core are the structural proteins p 18 and p24, which are produced by the proteolytic cleavage of p55, the gag precursor polyprotein (Essex et al., 1985; Montagnier, 1985; Ratner et al., 1985) . Ferns et al. (1987) recently produced a panel of monoclonal antibodies (MAbs) against the gag proteins p18 and p24 of a British isolate of HIV, CBL-1 (Weiss et al., 1985) . In this paper we describe the expression of p 18 sequences in Escherichia coli, the mapping of the epitopes of five p 18-reactive MAbs and fluorescence-activated cell sorter analysis (FACS) of HIV-infected cells using the MAbs. In the accompanying paper (Spence et al., 1989) we describe the cloning of the sequences encoding the p18 and p24 proteins from the CBL-1 isolate, the expression of p24 sequences and the epitope mapping of six anti-p24 MAbs.
METHODS
Construction of the p18 expression plasmids. All plasmids were constructed from the HIV-1 clones pDM608 (see accompanying paper) or pB2 (Benn et at., 1985) . pDM614 was made as previously described (Spence et al., 1989) . pDM612 was made as follows. After digestion of pDM608 with TaqI and EcoRI a 1215 bp fragment was gelpurified, the recessed ends were filled in with Klenow DNA polymerase and cloned into SmaI-digested pUC 19. A recombinant, pDM610, in which the original TaqI site of the insert was proximal to the EcoRI site of the vector, was digested with PvulI to produce a 422 bp fragment containing most of the coding region for p 18 together with 5' sequences from pUC 19. BamHl linkers of 8 bp were ligated to the ends of the fragment which was then digested with both EcoRI and BamHI. The 340 bp product was cloned into the EcoRI-and BamHI-digested pXY460 expression vector (Spence et al., 1989) . pDM602 was made from pB2 in a similar manner, except that because of methylation of the TaqI site at position 377 [nucleotide numbering from Wain-Hobson et al. (1985) ] only the TaqI site at position 232 was cleaved. This meant that the fragment expressed in pXY460 and all the intermediate fragments were 145 bp larger than their CBL-I counterparts, pDM610 was digested with NciI, followed by purification of a 1359 bp fragment, containing pUC19 and HIV-1 sequences, on an agarose gel. The recessed ends were filled in with Klenow polymerase followed by digestion with EcoRl to produce a 1044 bp fragment containing most of the coding region for both p 18 and p24, together with sequences 5" from pUC19. The fragment was then ligated into EcoRI-and SmaI-digested pXY460 to produce the expression construct pDM635.
Two oligonucleotides were made, one complementary to the non-coding strand at the extreme 5' end of the p 18 coding region (190/1-5') containing an EcoRI site at its 5' end and the other complementary to the coding strand at the 3' end of the p 18 coding region (190/l-Y) containing the complement of two TAG stop codons and a BamHI site at its 5' end. A polymerase chain reaction (PCR; Saiki et al., 1985) was then carried out as follows. To 200 ng of plasmid pDM608 was added 1 ~tg of each primer, dATP, dCTP, dGTP and dTTP all to a final concentration of 1 mM, gelatin to 2 mg/ml, PCR buffer (20 mM-Tris-HC1 pH 8.8, 5 m~,f-MgC12, 5mM-dithiothreitol and 50 mMNaCI) and 2.5 units of Tag polymerase (Biolabs). This mixture was overlaid with 50 pl liquid paraffin. The plasmid was denatured (2-5 min at 95 °C), followed by annealing of the primers (40 °C for 2 min); polymerization was carried out by incubation at 70 °C for 2 rain. This procedure was repeated nine times. After purification, the DNA was digested with EcoRI and BamHl followed by agarose gel electrophoresis. A single band of 418 bp was removed from the gel and ligated into EcoRI-and BamHI-digested pXY46x, a derivative of pXY460 in which most of the fl-galactosidase coding region had been removed, followed by the addition of multiple stop codons 3' to the BamHI site (D. Parker, unpublished results) to produce the plasmid pDM641.
Expression of the recombinant proteins in E. coil The above recombinants were recovered by transforming TG 1 cells, a derivative of JM 101 (Gibson, 1984) , followed by selection of blue colonies in the case of the fl-galactosidase fusion proteins, after plating onto LB agar containing 100 ttg/ml ampicillin and 40 ~tg/ml 5-bromo-4-chloro-3-indolyl-fl-D-galactoside if fusion proteins were being expressed, or by plating onto LB agar with ampicillin alone for non-fusion protein products. Further selection was carried out on all recombinants by small-scale DNA preparation (Maniatis et al., 1982) and restriction analysis. Fusion proteins were induced by the method described in the accompanying paper.
Western blot and immunoprecipitation analysis of expressed proteins. Bacterial cell lysates were run on 10 ~ or 10 to 25~ gradient SDS-PAGE gels (Laemmli, 1970) and processed as described (Spence et aL, 1989) .
Preparation of deletion mutants of p18. Deletions were carried out on the pDM612 construct using exonuclease Bal 31, essentially by the method of Maniatis et al. (1982) , following digestion with BamHl. The Bal 31-digested vector was then cut with EcoRl and the shortened expression fragments were purified from agarose gels. These samples were then religated into EcoRI-, Sinai-digested pXY460 and fusion protein-expressing transformants were selected as above.
Sequence analysis. Analysis was carried out on fragments cloned into the expression vectors pXY460 and pXY46x using Sequenase (United States Biochemical), in a modification (Tabor & Richardson, 1987) of the dideoxynucleotide chain terminator procedure of Sanger et al. (1977) . Oligonucleotides complementary to the sequences 5' and 3' to the polycloning site of pXY460 and pXY46x were synthesized such that the sequences generated included this polycloning site. To sequence the entire p18 expression fragment a series of oligonucleotides complementary to both strands of the fragment were synthesized.
Peptide analysis. A series of four overlapping peptides representing the carboxy-termina145 amino acids of p 18 were synthesized, such that peptide 246 was 45 amino acids long, peptide 248 contained 23 amino acids from the amino terminus of this region, peptide 250 contained 22 amino acids from the carboxy terminus of this region and peptide 252 shared 11 amino acids with peptide 248 and 12 amino acids with peptide 250 (see Fig. 6 ).
Microtitre plates were coated at 4 °C overnight with 100 ~tl per well of peptide (to molar concentrations equivalent to 4 ~tg/ml of peptide 250 in 15 mM-Na2CO3, 35 mM-NaHCO3). The plates were then washed in phosphate-buffered saline (PBS; 0.15 M-NaC1, 0.15 M-Na3PO4, pH 7.2) before dilutions of the MAbs in PBS containing 2% skimmed milk powder were added. Following incubation at 37 °C for 2 h the plates were washed and 50 pl/well horseradish peroxidase-labelled, rabbit anti-mouse IgG was added followed by incubation at 37 °C for 1 h. After washing 50 Ixl of peroxide--o-phenylene diamine substrate solution in citrate buffer was added. After optimum eolour development the reaction was stopped using 12-5 % sulphuric acid. Absorbance values were read at 492 rim.
Immunofluorescent staining and FA CS analysis of the MAbs. All staining was done on the H9 cell line (courtesy of M. Popovic) infected with the following isolates of HIV-1 : human T-cell leukaemia virus type IIIb (HTLV-IIIb), et al., 1979) and Leu3a (anti-CD4) (Evans et al., 1981) . Freshly passaged H9 cells were incubated at 40 °C for 30 min at a concentration of 2 × 106 cells/ml with 50 gl of MAb or control antibody. The cells were washed and resuspended in 50 gl of rabbit anti-mouse-fluorescein isothiocyanate (FITC) (Dako) at a 1 : 50 dilution for 30 min. After washing, the cells were fixed overnight at 4 °C in 1 ~ formaldehyde. Flow analysis was carried out on a Becton Dickinson FACS IV and the results were recorded as mean peak fluorescence and percentage of cells positive as compared to controls without a first antibody label.
RESULTS

Expression of recombinant p18 from the CBL-1 and pB2 clones
To give correct framing at the 5' end of the p18 expression fragment we cloned the bluntended TaqI-, EcoRI-digested fragment into SmaI-cut pUC19 and selected a recombinant in which the orientation of the insert placed the 5' end of the p18 open reading frame (ORF) proximal to the EcoRI site of the vector. After digestion at the EcoRI site there remain 18 nucleotides of pUC19 sequence at the 5' end of the pI8 coding fragment which result in the correct expression of the p18 O R F in pXY460 (Fig. l a) . As a consequence of this cloning strategy, the fusion protein product of the plasmid pDM612 should express seven amino acids encoded by the expression vector and p U C 19 before the first HIV-encoded residue, which is the 15th amino acid of p18. The position of the 3' cloning site results in the loss of 13 amino acids at the carboxy terminal of the p 18 recombinant protein. After induction, S D S -P A G E and staining with Coomassie Brilliant Blue the pl8-fl-galactosidase fusion protein is visible as a band of approximately 128K which also reacts, after Western blotting, with a specific anti-pl8 M A b (Fig. 1 b) . After BamHI and EcoRI digestion of the pl 8 coding region from the clone pB2 we isolated a 485 bp fragment, rather than the 340 bp fragment expected. Sequence analysis indicated that the 5' TaqI site was the one at nucleotide position 232 [numbering from Wain-Hobson et al. (1985) used throughout] which was probably retained due to the methylation sensitivity of the TaqI site at position 377 in the pB2 clone. Within the 145 bp region at the 5' end of this fragment are stop codons in all three frames, the stop codon in the ORF expressed from the vector terminates t 1 bp 5' to the initiation codon of plS. However after induction and SDS-PAGE a fusion protein is visible which migrates at approx. 134K. This protein reacts with a pl 8-specific MAb (Fig. 2) . The ability of the pDM602 plasmid to express the p18 protein is possibly due to the prokaryotic ribosome-binding sequence motif of AGGAG falling four bases 5' to the methionine initiation codon of p18. Frameshift mutagenesis of pDM602 to prevent any potential readthrough from the vector-encoded ribosome-binding site did not significantly reduce the expression of the fusion protein (data not shown), further suggesting that the HIV ribosome-binding motif is active in this system.
Sequence of CBL-1 p18
The p18 coding fragment in the plasmid pDM612 was sequenced. Only one base change compared to HTLV-IIIb and LAV was detected, at position 559 (G to T). This change causes an amino acid substitution (arginine for leucine) when compared to both LAV and HTLV-IIIb (Sanchez-Pescador et al., 1985; Wain-Hobson et al., 1985) . As the pDM614 plasmid contained 38 bp from the 3' end of the p 18 coding region at the 5' end of the p24 coding region (Spence et al., 1989 ) the 5' end of this expression fragment was also sequenced. A variation from the LAV sequence at position 714 was observed (CBL-1, T; HTLV-IIIb, T; LAV, C) which did not cause an amino acid substitution. 
Characterization of the anti-HIV-1 MAbs using the pDM612 and pDM602 fusion protein products
A panel of six M A b s previously described by Ferns et al. (1987) were screened against the fusion products of pDM602, pDM612 and pDM614 on Western blots against pDM612 in immunoprecipitation assays. The results are shown in Table 1 . The M A b l 1 H9 reacted with the product of the pl8-expressing plasmids pDM602 and pDM612 on Western blots and with pDM612 in immunoprecipitation assays, indicating that its epitope fell somewhere within the body of p18. 4H2B1 reacted on Western blots with the product of the plasmid pDM614 indicating that its epitope fell within the 12 amino acids at the carboxy terminus of p18. The M A b 1D9 failed to react with the products of either pDM602, pDM612 or pDM614 on Western blots; however, it did react with the pDM614 product in immunoprecipitation assays. This would indicate that the epitope for this M A b is located within the 12 carboxy amino acids of pl 8 and may also be subject to some conformational restraints. The M A b 9G5, which was shown by Ferns et al. (1987) to be an IgM, did not produce a signal on Western blots as the detection system used was IgG-specific, but did precipitate the product of plasmid pDM612 indicating that its epitope fell within the body of p 18. The M A b CH9B2 reacted on Western blots only with the product of the plasmid pDM602. As discussed above this plasmid probably expresses the amino-terminal amino acids of pl 8 which pDM612 does not, suggesting that the epitope for this M A b falls within the 14 amino-terminal amino acids of p 18. The MAb'4C9 failed to react with any of the recombinant proteins. A series of constructs expressed p18 as a fusion protein containing carboxy amino acid deletions. When 11H9, the only anti-pl8 M A b reactive with the pDM612 product on Western blots, was screened its binding was prevented by the shortest deletion (14 bp or five amino acids) (Fig. 3) . This suggests that 11 H9 requires a four amino acid region (Gln-Gln-Ala-Ala) encoded by nucleotides 680 to 692 for its binding.
To demonstrate that the free carboxy terminus of p 18 was required for the binding of 1D9, we made two further constructs, one of which contained the carboxy amino acid sequence of p18 and another which mimicked the p55 precursor protein around this site. We used P C R to generate the correct carboxy amino acid sequence. The oligonucleotides used to amplify the p 18 coding region also contained appropriate restriction sites to facilitate cloning. As a consequence, the amino terminus contained three amino acids encoded by the oligonucleotide and the expression vector (Fig. 4a) . The Mr of the predicted product encoded by this fragment should have been 15217; the product visualized after Western blotting appeared to be about 17K to 18K, compatible with the observation that the viral p18 protein migrates at 17K to 18K (Veronese et al., 1988) , although its Mr derived from amino acid composition is 14884. Fig. 4(b) shows the reactivity of this protein with a series of MAbs. 3D3 (anti-p24) does not react with the recombinant pl 8 (panel A) whereas all the p 18 MAbs, including 1D9, do. The band migrating at approximately 25K in both the fusion protein containing lanes (2 and 3) probably represents a /~-galactosidase degradation product. The E. coli lysates were prepared using lysozyme, consequently a strong signal representing this protein can be seen at 14K in all lanes. pDM635 was made such that the 1044 bp fragment contained, at its 5' end, the same sequences as the expression fragment from pDM612 and at its 3' end the same sequences as the expression fragment from pDM614 (Fig. 1 a) . After induction and SDS-PAGE a fusion protein of approximately 154K was visible on Coomassie-stained gels; these proteins also reacted with MAbs against both p18 and p24 (Fig. 5) . However, MAb 1D9 failed to react although the amino acids predicted to form its epitope were present at the carboxy end of the pl 8 protein sequence. As shown in Table 1 the virus-expressed p55 is not bound by 1D9.
Reactivity of the M A b with peptides representing part o f the sequence o f p18
Binding of three MAbs (1D9, 11H9 and 4H2B1) to the four peptides is shown in Fig. 6 . MAb ID9 reacted with the peptides 246 and 250 but not with 248 or 252 indicating that its epitope falls within the last 10 carboxy amino acids of p 18.11 H9 reacted equally well with peptides 246 and 252, less well with peptide 248 and not at all with peptide 250. This implies that the epitope recognized by this antibody may be located within the region of the carboxy terminus of peptide 
Cell surface p18 staining
None of the anti-p 18 MAbs tested reacted with uninfected H9 cells, although W6/32 stained these cells strongly. Analysis of the HIV-infected cells revealed staining with all antibodies to p18 on all isolates of HIV-1 and with two MAbs on the LAV-2 isolate (Table 2 ). There was some variability of staining depending on both the MAb used and the isolate of HIV. The MAb 4H2B1 consistently stained all HIV-1 isolates although giving only a very weak reaction with LAV-2 (Fig. 7) . As previously described, CD4 was present on H9 cells and was down-regulated on those persistently infected with HIV. HLA class I staining was strong on both uninfected and infected cells.
DISCUSSION
The use of recombinant proteins produced in E. coli to characterize MAbs raised against HIVinfected human material allows one to identify those which react with cellular rather than viral antigens. Although hybridoma supernatants that reacted only with infected cells were chosen (Ferns et al., 1987) , it is possible that infected CEM cells express endogenous proteins that uninfected CEM cells do not and it is highly unlikely that E. coli would express products that would cross-react with these proteins. It was recently reported that MAbs that react with HIV p18 can also react with human cellular antigens (Parravicini et al., 1988) ; the authors suggested that HIV-1 could display some sort of molecular mimicry. If this were the case we would have expected to see a reaction of the MAb 4C9 with at least one of the recombinant proteins, as this MAb reacts well on Western blots with a protein migrating at 18K derived from infected human cells. The FACS analysis using anti-pl8 MAbs on live, infected H9 cells has revealed that p18 appears to be present on the surface of these cells. The FACS results for 4C9 (not shown) suggest that its epitope is present on uninfected H9 cells. All the other p18 MAbs react with one or other of the fusion protein products of the p 18 expression plasmids.
Epitope targets for most of the MAbs to the carboxy-terminal 45 amino acids of p18 were identified. Only one MAb, CH9B2, appeared to react near the amino terminus of p18. This MAb also reacted with LAV-2 by FACS. Analysis of the amino terminus of HTLV-IIIRF and LAV-2 shows that they share 10 of the 14 amino acids within the epitope region of CH9B2.
HTLV-IIIb, which reacts poorly on FACS with CH9B2, differs from HTLV-IIIRF by a single glutamine for lysine substitution at amino acid position 12. Conclusions drawn at this stage must be drawn with caution as CH9B2 was raised against the CBL-1 isolate of HIV-1 and no sequence data for its epitope are presently available. Further work with overlapping peptides would be required to identify precisely the target for this MAb.
Of the MAbs whose epitopes cluster at the carboxy terminus of plS, 1D9 is the most interesting. Its epitope falls within the 12 carboxy amino acids ofpl8 and does not appear to be exposed (or exist) on the precursor protein p55. Although we have clearly located the target for this MAb the FACS data cannot easily be interpreted. This may be because non-contiguous sequences of similar but not identical amino acids may be all that are required for some antibodies to bind. As in other human retroviruses the amino terminus of p18 is myristylated (Veronese et al., 1988) . The exact function of the myristic acid moiety is not clear, although it may play a role in intracytoplasmic transport to the site of budding (Rein et al., 1986) . pl8 is a hydrophilic protein (589/oo hydrophilic amino acids, 34 ~ hydrophobic) with alternate groups of hydrophilic and hydrophobic amino acids terminating in a long hydrophilic carboxy terminus. On the amino side of the terminal hydrophilic region is a block of 13 hydrophobic amino acids. One might therefore speculate that p 18 is a membrane-associated protein, the amino terminus of which is anchored to the lipid membrane by the myristic acid moiety, the majority of its amino acids locating on the inside of the cell/viral membrane (Gelderblom et al., 1987) with the short hydrophobic amino acids holding the protein in place and a transmembrane region enabling the carboxy terminus to be presented extracellularly. The presence of the epitopes for all but one of the anti-p 18 MAbs within the terminal carboxy region and the results of the FACS analysis do suggest an extracellular position for this region.
This model is also supported by the work of Gelderblom et al. (1988) who demonstrated that whereas most MAbs directed against p 18 reacted with epitopes located under the lipid bilayer, antibodies against a peptide HPG-30, showing homology to thymosin, reacted with determinants on the outer surface of the membrane. HPG-30 is homologous to the carboxy terminal sequences of p 18 and antibodies reacting with it also react with HIV-1 p 18 (Naylor et al., 1987) . It is possible, however, that pl8 may bind cell membranes extracellularly as a consequence of virus particle degradation in culture, leading to FACS results similar to those described above.
The use of PCR to generate a fragment encoding the precise amino acid sequence of viral pl 8 is yet another example of the power of this technique. In the future we can expect PCR to complement many in vitro mutagenesis methods, allowing the rapid production of precise expression systems.
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